CVRx (NASDAQ:CVRX) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of CVRx (NASDAQ:CVRX) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports.

CVRX has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CVRx in a report on Monday, December 29th. Canaccord Genuity Group lowered their price target on shares of CVRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.20.

CVRx Trading Up 8.9%

NASDAQ:CVRX opened at $5.28 on Tuesday. CVRx has a 12 month low of $4.30 and a 12 month high of $14.48. The firm has a fifty day simple moving average of $6.87 and a 200-day simple moving average of $8.00. The company has a current ratio of 7.63, a quick ratio of 8.60 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $138.92 million, a P/E ratio of -2.58 and a beta of 1.31.

CVRx (NASDAQ:CVRX) last released its earnings results on Thursday, February 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04). The firm had revenue of $16.02 million during the quarter, compared to analyst estimates of $15.75 million. CVRx had a negative net margin of 94.10% and a negative return on equity of 99.32%. On average, equities research analysts anticipate that CVRx will post -1.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stoneridge Investment Partners LLC boosted its stake in shares of CVRx by 7.9% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 20,126 shares of the company’s stock worth $162,000 after acquiring an additional 1,471 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of CVRx by 10.7% in the 3rd quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after purchasing an additional 1,700 shares in the last quarter. Cresset Asset Management LLC raised its holdings in CVRx by 3.5% in the 2nd quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock worth $315,000 after purchasing an additional 1,823 shares during the period. Barclays PLC boosted its position in CVRx by 9.8% during the fourth quarter. Barclays PLC now owns 25,262 shares of the company’s stock worth $179,000 after purchasing an additional 2,257 shares in the last quarter. Finally, Larson Financial Group LLC boosted its position in CVRx by 155.6% during the fourth quarter. Larson Financial Group LLC now owns 5,426 shares of the company’s stock worth $39,000 after purchasing an additional 3,303 shares in the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.